Dr. Christopher John Ong

Dr. Christopher John Ong

B.Sc. University of British Columbia, 1988
Ph.D. University of British Columbia, 1996

Team: 
Clinical and Research Scientists
Positions: 

Senior Research Scientist, Vancouver Prostate Centre
Associate Professor, Department of Urologic Sciences, University of British Columbia

 

A key area of focus of Dr. Ong's research program is to understand the molecular mechanisms that govern prostate cancer growth and treatment resistance.  His primary focus has been focused on defining and targeting cell signalling pathways underlying the development and progression of prostate cancer and to develop new therapeutic strategies to improve survival.  Dr. Ong and colleagues have recently discovered a critical secreted cell signaling protein called SEMA3C that drives cancer growth. From this discovery, they developed a novel protein-based medication that disrupts SEMA3C signaling and prevents unhealthy cell growth that leads to prostate cancer, and potentially other cancers.

Dr. Ong is also a co-discoverer/inventor of a novel class of small molecule agonists of the SH2-containing inositol phosphatase, SHIP. This technology was licensed to Aquinox Pharmaceuticals, a UBC spin-off company that Dr. Ong co-founded with his colleagues, Drs. Mui, Andersen and Krystal. Aquinox’s lead drug candidate, Rosiptor, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Building upon the positive Phase 2 trial results where AQX-1125 demonstrated an ability to improve both pain and urinary symptoms in patients with Interstitial Cystitis Bladder Pain Syndrome (IC/BPS), Rosiptor is now in multicenter Phase 3 clinical trials for treatment of IC/BPS.  Top-line data from the LEADERSHIP 301 trial is anticipated in the third quarter of 2018. 

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

VPC Terry Fox team 2016

Terry Fox Run: Sunday September 16, 2018

On Sunday September 16, the fundraising Terry Fox walk/run/ride is taking place across Canada.  We are grateful for our  grant support provided by The Terry Fox Foundation and Terry Fox Research Institute continously since 1998 - click here to donate to our team (opens in new window)

 

Vancouver

18th Annual Pacific Northwest Prostate Cancer Conference: Sat Sept 22, 2018

The 18th Annual Pacific Northwest Prostate Cancer Conference for patients, their families and health care professionals will be held in Vancouver on Saturday September 22, from 8 AM to 4 PM.  Click here for further details and to purchase tickets ($30, includes lunch). (Opens in new window)

 

Employment

Work at the Vancouver Prostate Centre

Thursday, July 26, 2018

Dr. Gleave awarded the 2018 Dr. Chew Wei Memorial Prize in Cancer Research

Dr. Gleave
Tuesday, May 29, 2018

Three VPC trainees receive 2018 VCHRI Rising Star Awards

2018 Rising Star Awardees
DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.